Advanced in Lung Cancer

Xiaoqing H. Liu

8 Dongda Street, 
Beijing, CN 
Advanced in Lung Cancer
8 Dongda Street, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Xiaoqing Liu practices in Beijing, China. Liu is rated as an Advanced expert by MediFind in the treatment of Lung Cancer. Their top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and EGFR Positive Lung Cancer.

Their clinical research consists of co-authoring 132 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 84 articles and participated in 2 clinical trials in the study of Lung Cancer.

Locations

8 Dongda Street, Beijing, 100071, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib
Enrollment Status: Completed
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

132 Total Publications

Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers.
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers.
Journal: Med (New York, N.Y.)
Published: December 28, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile